```html

Medulloblastoma – Comprehensive Medical Guide

Overview

Medulloblastoma is a malignant (cancerous) brain tumor that originates in the cerebellum, the part of the brain that controls balance and coordination. It belongs to a family of tumors called “primitive neuro‑ectodermal tumors” (PNETs) and is the most common malignant brain tumor in children, accounting for about 20% of all pediatric brain tumors.

• Age groups affected: Primarily children aged 3‑8 years, but it can also occur in adolescents and, rarely, in adults (≈1% of all medulloblastoma cases).
• Incidence: Approximately 1.5 cases per million people per year in the United States (≈600 new cases annually). The incidence is slightly higher in males (about 1.5‑1.6 : 1 male‑to‑female ratio).
• Geography: Rates are fairly consistent worldwide, though some Asian studies suggest a modestly higher incidence in East Asian populations.

Because the tumor arises in the posterior fossa (the region at the base of the skull), it can quickly block the flow of cerebrospinal fluid (CSF), leading to increased intracranial pressure. Prompt diagnosis and treatment are essential for survival and long‑term quality of life.

Symptoms

Symptoms reflect the tumor’s location in the cerebellum and its tendency to obstruct CSF pathways. They may develop gradually or present abruptly.

Neurologic symptoms

• Headache: Often worse in the morning or when lying down; may be accompanied by nausea.
• Vomiting: Typically non‑bilious and may be projectile, especially in children.
• Ataxia (loss of coordination): Unsteady gait, difficulty walking or climbing stairs.
• Truncal instability: Trouble sitting upright without support.
• Dysmetria: Inaccuracy of purposeful movements (e.g., overshooting a target when reaching).
• Vertigo or dizziness.
• Double vision (diplopia) or other visual disturbances.

Signs of increased intracranial pressure

• Swollen optic discs (papilledema) seen on eye exam.
• Changes in mental status – irritability, lethargy, or confusion.
• Bulging fontanelle in infants.
• Severe, persistent headache that does not respond to usual pain relievers.

Other possible manifestations

• Difficulty with fine motor skills (e.g., writing, buttoning).
• Hearing changes or tinnitus (rare).
• Hormonal disturbances if the tumor spreads to the spinal cord (leptomeningeal dissemination).

Causes and Risk Factors

The exact cause of medulloblastoma is unknown, but research has identified several genetic and environmental contributors.

Genetic factors

• Inherited syndromes:
  • Gorlin syndrome (PTCH1 mutation) – increases risk of medulloblastoma, especially the Sonic Hedgehog (SHH) molecular subtype.
  • Li‑Fraumeni syndrome (TP53 mutation) – predisposes to many childhood cancers, including medulloblastoma.
  • Neurofibromatosis type 1 – rare association.
• Somatic mutations: Alterations in genes such as MYC, CTNNB1, SMO, and TP53 are frequently found in tumor tissue.
• Chromosomal abnormalities: Isochromosome 17q is a common cytogenetic hallmark.

Environmental & other risk factors

• Exposure to high‑dose ionizing radiation to the head (e.g., therapeutic radiation for other conditions) – rare but documented.
• No convincing link to parental smoking, alcohol, or occupational exposures.
• Age and male sex are modest, non‑modifiable risk factors.

Diagnosis

A multidisciplinary team (neurologist, neurosurgeon, pediatric oncologist, radiologist, neuropathologist) is typically involved.

Imaging studies

• Magnetic Resonance Imaging (MRI) with contrast: First‑line test; shows a well‑circumscribed, often enhancing mass in the cerebellar vermis or hemispheres. Diffusion‑weighted imaging helps differentiate medulloblastoma from other posterior fossa tumors.
• CT scan: Used in emergencies to detect hydrocephalus or calcifications; less sensitive than MRI for tumor margins.
• Spinal MRI: Performed to evaluate for leptomeningeal spread (present in 10‑20% of cases at diagnosis).

Laboratory & pathology

• CSF cytology: Lumbar puncture (often after tumor resection) to look for malignant cells in the CSF.
• Biopsy / surgical resection: Tissue is examined under a microscope. Molecular classification (WNT, SHH, Group 3, Group 4) is now standard, as it guides prognosis and treatment.
• Genetic testing: Germline testing for syndromic mutations when a hereditary risk is suspected.

Staging

The Chang staging system (Stage 0‑IV) assesses extent of disease, including spinal dissemination. Newer staging incorporates molecular subgroup and risk stratification (standard‑ vs. high‑risk).

Treatment Options

Treatment is multimodal and tailored to age, tumor molecular subtype, and risk category.

Surgery

• Goal: Maximal safe resection (gross‑total removal) while preserving neurologic function.
• In infants or very young children, a less aggressive resection may be chosen to avoid damage to the developing cerebellum.

Radiation therapy

• Post‑operative craniospinal irradiation (CSI): Standard for children >3 years old. Typical dose: 23.4 Gy to the entire neuraxis plus a boost (54‑55 Gy) to the posterior fossa.
• Proton beam therapy: Offers similar tumor control with reduced dose to surrounding tissue, decreasing long‑term cognitive and endocrine side effects.
• Patients under 3 years often receive chemotherapy first to postpone radiation because of the severe neurocognitive impact of CSI on very young brains.

Chemotherapy

• Common regimens: Cyclophosphamide, Vincristine, Carboplatin, Cisplatin, and Etoposide. The “POG” (Pediatric Oncology Group) and “CCG” (Children’s Cancer Group) protocols are widely used.
• High‑dose chemotherapy with autologous stem‑cell rescue may be considered for high‑risk or recurrent disease.

Targeted & experimental therapies

• SHH inhibitors (e.g., Vismodegib, Sonidegib): Proven benefit in SHH‑activated tumors, especially in adult patients.
• Immunotherapy: Trials investigating checkpoint inhibitors and CAR‑T cells are ongoing.
• Clinical trials: Participation is encouraged when available; registries such as ClinicalTrials.gov list ongoing studies.

Supportive & lifestyle measures

• Control of intracranial pressure (ventriculoperitoneal shunt or external ventricular drain) before definitive treatment.
• Physical and occupational therapy to address ataxia and motor deficits.
• Endocrine monitoring (growth hormone, thyroid, adrenal) because radiation can affect the hypothalamic‑pituitary axis.
• Neurocognitive rehabilitation and educational support for children.

Living with Medulloblastoma

Survivorship care is a lifelong process.

Follow‑up schedule

• First 2 years: MRI of brain and spine every 3‑4 months.
• Years 3‑5: MRI every 6 months.
• After 5 years: Annual MRI, or more often if symptoms recur.
• Annual endocrine evaluation and neurocognitive testing.

Daily management tips

• Medication adherence: Keep a written schedule for chemotherapy cycles, anti‑seizure meds, or steroid tapers.
• Hydration & nutrition: Adequate fluids help reduce risk of kidney toxicity from cisplatin; a balanced diet supports healing.
• Physical activity: Tailored balance and coordination exercises (under PT guidance) improve gait and reduce fatigue.
• School & work accommodations: Request an Individualized Education Plan (IEP) or workplace modifications for cognitive side‑effects.
• Psychosocial support: Counseling, support groups, and survivorship programs reduce anxiety and depression.
• Vaccinations: Stay up‑to‑date; avoid live vaccines for a few months after high‑dose chemotherapy.

Long‑term side effects to monitor

• Hearing loss (cisplatin toxicity)
• Secondary malignancies (radiation‑induced)
• Growth hormone deficiency
• Learning difficulties or memory problems
• Hormonal imbalances (thyroid, adrenal)

Prevention

Because most cases are sporadic and linked to non‑modifiable genetic events, primary prevention is limited.

• Genetic counseling: Families with known hereditary cancer syndromes (e.g., Gorlin, Li‑Fraumeni) should receive counseling and consider surveillance protocols.
• Avoid unnecessary radiation exposure: Use MRI instead of CT when feasible, especially in children.
• Healthy prenatal environment: No proven link, but avoiding known teratogens (e.g., high‑dose radiation, certain chemotherapy) during pregnancy is prudent.

Complications

If left untreated or if treatment fails, medulloblastoma can lead to serious, life‑threatening problems.

• Hydrocephalus: Blockage of CSF flow → severe intracranial pressure, brain herniation.
• Leptomeningeal dissemination: Tumor cells spread through CSF, causing spinal cord compression, new neurologic deficits, and widespread disease.
• Brainstem compression: May cause respiratory compromise or loss of vital reflexes.
• Seizures: Resulting from irritation of cortical tissue.
• Secondary cancers: Radiation or chemotherapy can induce future malignancies.
• Severe neurocognitive decline: Particularly in children who receive high‑dose craniospinal radiation before age 3.

When to Seek Emergency Care

References

• Mayo Clinic. Medulloblastoma. https://www.mayoclinic.org/diseases‑conditions/medulloblastoma
• American Cancer Society. Brain and Spinal Cord Tumors in Children. 2024.
• National Cancer Institute. PDQ® Cancer Information Summaries – Medulloblastoma Treatment (PDQ®)–Patient Version. https://www.cancer.gov/types/brain/patient/medulloblastoma-treatment-pdq
• World Health Organization. Classification of Tumours of the Central Nervous System, 5th edition. 2021.
• Cleveland Clinic. Medulloblastoma in Children. https://my.clevelandclinic.org/health/diseases/14974‑medulloblastoma
• St. Jude Children’s Research Hospital. Medulloblastoma Clinical Trials. https://www.stjude.org/clinical‑trials/medulloblastoma

```